{"id":3841,"date":"2021-10-04T05:30:32","date_gmt":"2021-10-04T09:30:32","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/"},"modified":"2026-09-24T00:07:15","modified_gmt":"2026-09-24T04:07:15","slug":"les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/","title":{"rendered":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre"},"content":{"rendered":"\nParis, France, le 4 octobre 2021<\/strong>, 7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des pr\u00e9sentations orales sur LUMEVOQ\u00ae<\/sup> et GS030 seront donn\u00e9es lors des congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT en octobre. L\u2019\u00e9quipe de management participera et pr\u00e9sentera \u00e9galement \u00e0 plusieurs conf\u00e9rences Investisseurs au cours du m\u00eame mois d\u2019octobre.\n\n \n\nChardan 5th<\/sup> Annual Genetic Medicines Conference<\/u><\/strong>\n\n4-5 octobre 2021 \u2013 Virtuel<\/em><\/strong>\n\nBernard Gilly, Co-fondateur et Directeur G\u00e9n\u00e9ral, pr\u00e9sentera le lundi 4 octobre 2021, \u00e0 8h00 ET et l\u2019\u00e9quipe de management tiendra des r\u00e9unions Investisseur pendant la conf\u00e9rence.\n\nUn webcast de l\u2019interview sera disponible \u00e0 l\u2019adresse https:\/\/bit.ly\/3zZOGsM<\/a> pendant 90 jours.\n\n\u00a0<\/strong>\n\n\u00a0<\/strong>HealthTech Innovation Days (HTID) <\/u><\/strong>\n\n4-5 octobre 2021 \u2013 Virtuel<\/em><\/strong>\n\nL\u2019\u00e9quipe de management de GenSight Biologics tiendra des r\u00e9unions Investisseur pendant la conf\u00e9rence.\n\n\u00a0<\/strong>\u00a0<\/strong>\n\n2021 Advanced Therapies Congress LIVE<\/u><\/strong>\n\n5-6 octobre 2021 \u2013 ExCel, Londres (Royaume-Uni)<\/em><\/strong>\n\nDr Magali Taiel, Directrice M\u00e9dicale, pr\u00e9sentera LUMEVOQ\u00ae<\/sup> le mercredi 6 octobre 2021 \u00e0 13h30 GMT.\n\n \n\n2021 OIS @ ASRS<\/u><\/strong>\n\n7 octobre 2021 \u2013 San Antonio, Texas (Etats-Unis) & Virtuel<\/em><\/strong>\n\nDr Magali Taiel, Directrice M\u00e9dicale, pr\u00e9sentera le jeudi 7 octobre 2021 \u00e0 9h09 CDT.\n\n \n\n39th<\/sup> Annual Scientific Meeting of the American Society of Retina Specialists (ASRS)<\/u><\/strong>\n\n8-12 octobre 2021 \u2013 San Antonio, Texas (Etats-Unis)<\/em><\/strong>\n\n\u00a0<\/em><\/strong>\u201cOptogenetics in the Clinic: Safety and Efficacy Updates on the Phase I\/II Clinical Trial PIONEER<\/span>\u201d<\/em> sera pr\u00e9sent\u00e9 par le Dr <\/strong>Joseph Martel<\/strong>, University of Pittsburgh School of Medicine, Etats-Unis et Investigateur de l\u2019\u00e9tude PIONEER.\n
    \n \t
  • Pr\u00e9sentation orale<\/em><\/li>\n \t
  • Session: In the Pipeline<\/em><\/li>\n \t
  • Dimanche 10 octobre 2021 \u00e0 14h40 \u2013 14h46 CDT<\/em><\/li>\n<\/ul>\n\u00a0<\/strong>\n\n2021 ARM Cell & Gene Meeting on the Mesa<\/u><\/strong>\n\n12-14 octobre 2021 \u2013 Carlsbad, Californie (Etats-Unis) & Virtuel<\/em><\/strong>\n\nDr Magali Taiel, Directrice M\u00e9dicale, a pr\u00e9-enregistr\u00e9 une pr\u00e9sentation qui sera disponible durant toute la conf\u00e9rence.\n\n\u00a0<\/strong>\u00a0<\/strong>\n\n28th<\/sup> Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)<\/u><\/strong>\n\n19-22 octobre 2021 \u2013 Virtuel<\/em><\/strong>\n\n\u00a0<\/strong>\u201cThe phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON)<\/span>\u201d<\/em> sera pr\u00e9sent\u00e9 par le Dr <\/strong>Patrick Yu Wai Man<\/strong>, University of Cambridge, Royaume-Uni et Investigateur dans l\u2019\u00e9tude REFLECT.\n
      \n \t
    • Pr\u00e9sentation orale<\/em><\/li>\n \t
    • Session 1a: CNS & Sensory I<\/em><\/li>\n \t
    • Num\u00e9ro d\u2019abstract: OR3<\/em><\/li>\n \t
    • Mardi 19 octobre 2021 \u00e0 18h30 \u2013 18h45 CET<\/em><\/li>\n<\/ul>\n\u00a0<\/strong>\u201cPartial recovery of visual function in a blind patient after optogenetic therapy for non-syndromic Retinitis Pigmentosa<\/span>\u201d<\/em> sera pr\u00e9sent\u00e9 par le Dr <\/strong>Jos\u00e9-Alain Sahel<\/strong>, University of Pittsburgh School of Medicine, Etats-Unis et Co-fondateur de GenSight Biologics.\n
        \n \t
      • Pr\u00e9sentation orale<\/em><\/li>\n \t
      • Session 3: Towards innovative gene therapy trials <\/em><\/li>\n \t
      • Num\u00e9ro d\u2019abstract: INV36<\/em><\/li>\n \t
      • Mercredi 20 octobre 2021 \u00e0 19h15 \u2013 19h45 CET<\/em><\/li>\n<\/ul>\n\u00a0<\/strong>\u00a0<\/strong>\n\nBIO-Europe 2021 <\/u><\/strong>\n\n25-28 octobre 2021 \u2013 Virtuel<\/em><\/strong>\n\nL\u2019\u00e9quipe de management de GenSight Biologics tiendra des r\u00e9unions avec des partenaires potentiels pendant la conf\u00e9rence.\n\n\u00a0<\/strong>\u00a0<\/strong>\n\nL\u2019\u00e9quipe de management de GenSight Biologics pr\u00e9sentera \u00e9galement lors des conf\u00e9rences suivantes :\n\nMitochondrial Diseases Conference 2021 by Mitocon <\/strong>\/\/ 15-16 octobre, virtuel<\/em>\n\nAdvancing Gene Therapy 2021 <\/strong>\/\/ 18-20 octobre, Boston, USA &<\/em> virtuel<\/em>\n\n\u00a0<\/strong>\n

        \u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il. D\u00e9velopp\u00e9 dans le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), le principal produit candidat de GenSight Biologics, LUMEVOQ\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), est actuellement en cours d’examen pour enregistrement en Europe, et en phase III pr\u00e9alablement au d\u00e9p\u00f4t de la demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis (Biologics License Application<\/em> [BLA]).\n","protected":false},"excerpt":{"rendered":"

        Paris, France, le 4 octobre 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des pr\u00e9sentations orales sur LUMEVOQ\u00ae et GS030 seront […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73,78,79],"news-type":[74,75,76,77,80],"post-year":[],"class_list":["post-3841","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-topic-gs030","news-topic-company-and-personnel","news-type-product-candidates","news-type-clinical","news-type-corporate","news-type-conferences","news-type-finance"],"acf":[],"yoast_head":"\nLes r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 4 octobre 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des pr\u00e9sentations orales sur LUMEVOQ\u00ae et GS030 seront […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-04T09:30:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:15+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre\",\"datePublished\":\"2021-10-04T09:30:32+00:00\",\"dateModified\":\"2026-09-24T04:07:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/\"},\"wordCount\":741,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/\",\"name\":\"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-10-04T09:30:32+00:00\",\"dateModified\":\"2026-09-24T04:07:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/10\\\/04\\\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/","og_locale":"fr_FR","og_type":"article","og_title":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics","og_description":"Paris, France, le 4 octobre 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que des pr\u00e9sentations orales sur LUMEVOQ\u00ae et GS030 seront […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/","og_site_name":"GenSight Biologics","article_published_time":"2021-10-04T09:30:32+00:00","article_modified_time":"2026-09-24T04:07:15+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre","datePublished":"2021-10-04T09:30:32+00:00","dateModified":"2026-09-24T04:07:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/"},"wordCount":741,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/","name":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2021-10-04T09:30:32+00:00","dateModified":"2026-09-24T04:07:15+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/10\/04\/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Les r\u00e9sultats cliniques des th\u00e9rapies g\u00e9niques LUMEVOQ\u00ae et GS030 de GenSight Biologics seront pr\u00e9sent\u00e9s aux congr\u00e8s 2021 de l\u2019ASRS et de l\u2019ESGCT, ainsi qu\u2019\u00e0 plusieurs conf\u00e9rences en octobre"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3841"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3841\/revisions"}],"predecessor-version":[{"id":6804,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3841\/revisions\/6804"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3841"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3841"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3841"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3841"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}